🔎 Trials Near Me

Gara Jalqabaatti › Burkitt Lymphoma › Maryland

Qorannoo klinikaalii Burkitt Lymphoma Maryland keessatti

Qorannoo 11 Burkitt Lymphoma f Maryland keessatti hirmaatuu jiru.

Magaalota Maryland keessatti

Takkalaa qorannoo (Ingiliffa)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 2
366 Days – 46 Years · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • University of Maryland/Greenebaum Cancer Center, Baltimore
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 39 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT03150693

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 3 hanga 39 · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT05442515

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT03223610

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Namoota walitti qabaa jiraSadarkaa 2
365 Days · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Johns Hopkins Asthma & Allergy Center, Baltimore
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT07648264

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • University of Maryland, Baltimore
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 1 hanga 30 · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
365 Days – 25 Years · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT03959085

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT05389423

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • University of Maryland, Baltimore
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Sad-2025 · NCT04260022

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.